Previous 10 | Next 10 |
3 Penny Stocks to Watch in July 2022 While investing in penny stocks can be challenging, it can be a great way to make money in the stock market. Because they are so volatile, investors need to be careful when choosing the best penny stocks to buy. And, if done correctly, penny stocks...
3 Hot Penny Stocks to Watch in Mid-June 2022 With so much going on in the stock market right now, finding penny stocks to buy can be difficult. But if you know where to look and what to look for, you can find some high-quality penny stocks that are worth your investment. For that re...
Buying Penny Stocks on May 23rd? Here’s What You Need to Know After a rough week of trading for penny stocks and blue chips, there is a lot that investors need to keep track of right now. As we all know, penny stocks are extremely speculative. This means that staying up to da...
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming ® Manufacturing System, today announc...
Image source: The Motley Fool. iBio (NYSEMKT: IBIO) Q3 2022 Earnings Call May 12, 2022 , 4:30 p.m. ET Continue reading For further details see: iBio (IBIO) Q3 2022 Earnings Call Transcript
The following slide deck was published by iBio, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: iBio, Inc. 2022 Q1 - Results - Earnings Call Presentation
IBio's (NYSE:IBIO) Q1 2022 net loss widened 61% to $12.4M (-$0.06 per share) despite a ~155% year-over-year revenue increase. Revenue of ~$1.9M in the quarter compared to $765K in the prior-year period. iBio (IBIO) managed to beat on the top line while the bottom line came in-line. Operating ...
iBio, Inc. (IBIO) Q3 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Rob Lutz - Chief Financial and Business Officer Conference Call Participants Roy Buchanan - JMP Securities Presen...
iBio press release (NYSE:IBIO): Q3 GAAP EPS of -$0.06 in-line. Revenue of $1.94M (+155.3% Y/Y) beats by $1.74M. CEO comment: “We anticipate there may be a notable medical and business opportunity for our nucleocapsid-based COVID-19 vaccine candidate, as the durability and efficacy of t...
BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming ® Manufacturing System, today announces its financ...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...